Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Propofol for Emergence Agitation
NCT04142840Phase 1Unknown
- Sponsor
- Renji Hospital
- Start
- Nov 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dexmedetomidine in Emergence agitation (EA) (2 arms), sponsored by Renji Hospital. Primary endpoint: Recurrence rate of emergence agitation assessed by the Riker Sedation-Agitation Scale at 1 day. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Emergence agitation (EA)
Beyond the preview
Go deeper on NCT04142840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142840.